Business Wire

MA-ABIOMED

17.2.2021 14:05:09 CET | Business Wire | Press release

Share
Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors

Abiomed (NASDAQ: ABMD) announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors, effective immediately. Dr. Rolle will serve as a member of the Governance and Nominating Committee and Regulatory and Compliance Committee of the board. With the appointment of Dr. Rolle, the board now comprises of eight active directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005546/en/

Dr. Rolle is a neurosurgeon, Rhodes scholar, and former professional football player in the National Football League. He developed and published the Rolle Scoring System, a public health rating scale used to determine a developing country’s governance around helmet safety to prevent traumatic brain injury. He has been recognized by the Congress of Neurological Surgeons for demonstrating the best operative technique in the reconstruction of upper extremity motor function using intercostal nerve transfers after a traumatic brachial plexus injury. Dr. Rolle is the chairman of the Myron L. Rolle Foundation, which provides health, wellness and education services to underserved populations in the United States and the Bahamas. He is the founder of the CARICOM Neurosurgical Initiative, a capacity-building and health system-strengthening project for improved neurosurgical care in the Caribbean.

“As someone practicing medicine today, Dr. Rolle understands the role of medical technology in improving outcomes for patients,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “Dr. Rolle’s experience as a Rhodes scholar, professional athlete and physician will bring unique perspective to our board. His non-profit leadership in addressing health inequities will help advance Abiomed’s initiative to partner with hospitals in inner cities to reduce health disparities.”

“Dr. Rolle’s appointment reflects Abiomed’s commitment to ensuring we have a broad mix of skills and viewpoints on the board. We look forward to benefiting from Dr. Rolle’s experience as we continue to grow the company,” said Dorothy E. Puhy, lead independent director of the Abiomed Board of Directors and former executive vice president, chief operating officer and assistant treasurer at Dana Farber Cancer Institute.

“I am excited to join the Abiomed Board of Directors and contribute to the company’s long-term growth and success. Abiomed is a company I truly believe in. Its patients first mission aligns with my professional and personal desire to make a positive impact on the lives of others,” said Dr. Rolle. “I look forward to working with Abiomed management and my fellow directors to be a valuable contributor to the board, to further improve outcomes for patients, and to help provide access to Abiomed’s life-saving technology to more people.”

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates18.3.2026 08:30:00 CET | Press release

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The other terms of the agreement remain confidential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318826412/en/ Samsung Bioepis office in Songdo, Incheon, Republic of Korea Under the terms of the agreement, Samsung Bioepis will b

Epassi Appoints Three Senior Leaders to Accelerate European Growth18.3.2026 08:00:00 CET | Press release

Epassi Group, a leading European multi-benefits technology platform, today announced the appointments of Phil Jones as Chief Revenue Officer (CRO), Ross Seychell as Chief People Officer (CPeO), and Cho Hwang as Chief Technology Officer (CTO), strengthening its leadership team as the company enters its next phase of expansion. Cho Hwang joined Epassi on December 1, 2025. He brings extensive global technology leadership experience from companies including HelloFresh, Coupang, and Nordstrom. At Epassi, Cho leads the company’s technology strategy and engineering organisation as the platform continues to scale across Europe. His experience will support Epassi’s ambition to further expand its multi-benefits ecosystem for employers, employees, and partners. Phil Jones joined Epassi on March 2. He brings extensive experience across HR technology and the full Human Capital Management lifecycle, having held senior leadership roles across Sales, Revenue Operations, and Customer Success at global

AiDEN Are Collaborating With Volvo Group Through the Innovation Hub CampX in a Proof-of-Value Project Solving Real Customer Needs18.3.2026 05:00:00 CET | Press release

In December 2024, a new regulatory requirement was introduced in Poland related to SENT (System for Electronic Transport Supervision) for tracking high-risk goods transported within the country. In regard to this, a project to validate one of AiDEN's services/products within the platform was initiated. This was done in a project with Volvo Trucks through CampX, Volvo Group’s global innovation arena for technology and business transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317838896/en/ AiDEN’s SENT GEO compliance service displayed within a Volvo truck’s in-vehicle infotainment system, enabling automated geolocation reporting for Poland’s System for Electronic Transport Supervision (SENT). Developed through a collaboration between AiDEN Automotive and Volvo Group’s CampX innovation hub, the integrated solution allows fleets to meet SENT requirements without external GPS hardware or aftermarket installations

LTM Named NVIDIA Partner Network ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 202618.3.2026 03:30:00 CET | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as the NVIDIA Partner Network (NPN) ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 2026. The award recognizes LTM’s strong collaboration with NVIDIA and its growing impact in helping enterprises move from AI experimentation to scalable, enterprise-ready adoption. The NVIDIA Partner Network (NPN) brings together a global ecosystem of technology and consulting partners working closely with NVIDIA to deliver advanced AI solutions. Being an NPN partner is about collaborating deeply with NVIDIA to help clients transition from AI pilots to enterprise-scale deployments combining NVIDIA’s advanced AI technologies with LTM’s industry and domain expertise to drive real-world outcomes. The Rising Star Consulting Partner of the Year award highlights LTM’s momentum in delivering AI solutions that are production-grade, secure, and designed for enterprise scale. This NPN award is a significant rec

SES Successfully Prices €650 million of SPACE Hybrid Securities17.3.2026 23:00:00 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES Financing S.à r.l., a wholly owned subsidiary of SES, announced the successful launch and pricing of the PNC5.25 Subordinated Perpetual with Automatic Conversion Events (“SPACE”) hybrid transaction, guaranteed on a subordinated basis by SES and SES Americom. SES Financing S.à r.l. is rated Ba1 (stable) and BBB- (stable) by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye